Cargando…

Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis

BACKGROUND: No meta-analysis is yet available for the risk of metabolic syndrome (MetS) following androgen deprivation therapy (ADT) for men with prostate cancer. To summarize the evidence for the link between ADT and MetS or its components quantitatively with a meta-analysis including all studies p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bosco, Cecilia, Crawley, Danielle, Adolfsson, Jan, Rudman, Sarah, Van Hemelrijck, Mieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368630/ https://www.ncbi.nlm.nih.gov/pubmed/25794005 http://dx.doi.org/10.1371/journal.pone.0117344

Ejemplares similares

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
por: Crawley, Danielle, et al.
Publicado: (2018)

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus
por: Crawley, Danielle, et al.
Publicado: (2018)

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
por: Lin, E., et al.
Publicado: (2020)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: Lin, E., et al.
Publicado: (2021)

Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022)

Mortality following Hip Fracture in Men with Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2013)

Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study
por: Parker, Jonathan, et al.
Publicado: (2020)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results
por: Beckmann, Kerri, et al.
Publicado: (2019)

Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer
por: Golabek, Tomasz, et al.
Publicado: (2016)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
por: Braunstein, Lior Z., et al.
Publicado: (2014)

Serum glucose and risk of cancer: a meta-analysis
por: Crawley, Danielle J, et al.
Publicado: (2014)

Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients
por: Hemelrijck, Mieke, et al.
Publicado: (2013)

Obesity and cancer: the role of vitamin D
por: Shanmugalingam, Thurkaa, et al.
Publicado: (2014)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Your next clinical cancer research project: preparation in a multidisciplinary environment is key
por: Van Hemelrijck, Mieke, et al.
Publicado: (2017)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2017)

Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study
por: Bosco, Cecilia, et al.
Publicado: (2015)

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
por: Ferrari, Nicoletta, et al.
Publicado: (2017)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy
por: Blute, Michael L., et al.
Publicado: (2017)

Causes of death in men with localized prostate cancer: a nationwide, population‐based study
por: Van Hemelrijck, Mieke, et al.
Publicado: (2015)

Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy
por: Damani, Arees, et al.
Publicado: (2016)

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0
por: Russell, Beth, et al.
Publicado: (2018)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Steroid Hormone Biosynthesis Metabolism Is Associated With Fatigue Related to Androgen Deprivation Therapy for Prostate Cancer
por: Feng, Li Rebekah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cnvc9ftmiq2s2mc445pmckvtcc